The PVDOMICS initiative aims to redefine pulmonary hypertension classification by discovering molecular-based subtypes through deep clinical phenotyping and omic analyses in 1,500 participants.
Answers are grounded in this paper and cite their sources.
May guide molecular phenotyping in pulmonary hypertension; leaves open whether subtypes enhance risk stratification or therapy selection.
The NIH/NHLBI launched an initiative, “Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics (PVDOMICS)” that aims to augment the current PH classification based on shared biological features. PVDOMICS will enroll 1,500 participants with PH and disease and healthy comparators. Enrollees will undergo deep clinical phenotyping and blood will be acquired for comprehensive “omic” analyses that will focus on discovery of molecular-based subtypes of PVD through application of high dimensional model-based clustering methods. In addition to an updated, molecular classification of PVD, the phenomic data generated will be a rich resource to the broad community of heart and lung disease investigators.
No takes yet. Share an insight, caveat, or question.
Hemnes et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: